-

WhiteSwell Expands Leadership Team with Key Appointments

New vice president of clinical affairs and board of directors member will support advancement of eLym™ System therapy for acute decompensated heart failure

GALWAY, Ireland--(BUSINESS WIRE)--WhiteSwell, a company pioneering a new paradigm in the treatment of acute decompensated heart failure (ADHF), today announced the appointments of Ric Cote to its board of directors and Sergio Shkurovich as vice president of clinical affairs.

Ric Cote brings over three decades of experience in the medical device industry to the board. He is currently the CEO of Channel Medsystems, where he leads a team committed to empowering women to take control of their health. Prior to this role, he was executive vice president of global sales and business development for Conceptus, which was acquired by Bayer in 2013. Earlier in his career, he oversaw sales and marketing at Influence Medical, which was acquired by AMS in 2000.

Sergio Shkurovich joins WhiteSwell with more than 20 years of experience in clinical strategy and execution. He previously led clinical research programs for V-Wave, Medtronic and St. Jude Medical. During his career, Sergio has been intimately involved with pursuing therapies to manage heart failure, including implantable pressure sensors and interatrial shunts. At V-Wave, he led the development of the RELIEVE-HF study, a rigorous RCT evaluating the safety and efficacy of interatrial shunting. He earned his Ph.D. and an MBA from Northwestern University.

“We are thrilled to welcome Ric Cote and Sergio Shkurovich to our team. They bring a wealth of experience and visionary leadership to WhiteSwell,” said Eamon Brady, WhiteSwell CEO. “Sergio’s deep clinical knowledge and strategic vision, paired with Ric’s extensive industry expertise, will significantly strengthen our leadership team and our capabilities as we develop our therapy to enhance tissue decongestion by supporting the lymphatics in order to improve outcomes for patients with ADHF.”

About WhiteSwell

WhiteSwell is a patient-focused company dedicated to improving treatment of acute decompensated heart failure (ADHF), a primary cause of repeat hospitalization and emergency room visits. A privately held company, WhiteSwell is headquartered in Galway, Ireland. For more information visit www.whiteswell.com.

Contacts

WhiteSwell


Release Versions

Contacts

Social Media Profiles
More News From WhiteSwell

WhiteSwell Announces New Data Supporting Acute Decompensated Heart Failure Treatment with eLym System

GALWAY, Ireland--(BUSINESS WIRE)--WhiteSwell, a company pioneering a new paradigm in the treatment of acute decompensated heart failure (ADHF), announced today positive data from 21 patients treated in its DELTA-HF trial evaluating the WhiteSwell eLym™ System. The data were presented at the Technology and Heart Failure Therapeutics (THT) meeting in Boston by Jan Biegus, M.D., deputy scientific director at the Institute of Heart Diseases at Wroclaw Medical University in Poland. “Persistent conge...

WhiteSwell Announces Six-month Outcomes After eLym System Treatment for Acute Decompensated Heart Failure Patients in its DELTA-HF Study

GALWAY, Ireland--(BUSINESS WIRE)--WhiteSwell, a company pioneering a new paradigm in the treatment of acute decompensated heart failure (ADHF), announced today positive six-month follow-up data on the initial nine patients treated in its ongoing DELTA-HF trial evaluating the WhiteSwell eLym™ System. The data were presented by William Abraham, M.D., professor of medicine, physiology, and cell biology at The Ohio State University Wexner Medical Center, at the Technology and Heart Failure Therapeu...

WhiteSwell Announces Successful Treatment of Acute Decompensated Heart Failure Patients in its Early Feasibility DELTA-HF Study

GALWAY, Ireland--(BUSINESS WIRE)--WhiteSwell, a company pioneering a new paradigm in the treatment of acute decompensated heart failure (ADHF), announced today positive initial results from its ongoing DELTA-HF trial evaluating the WhiteSwell eLym™ System. The data were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2023 in Cleveland, Ohio. In DELTA-HF, a minimally invasive catheter-based system is introduced to facilitate the removal of excess fluid from the...
Back to Newsroom